Emerging modes-of-action in drug discovery.
暂无分享,去创建一个
Eric Valeur | Frank Narjes | Christian Ottmann | Alleyn T. Plowright | A. Plowright | C. Ottmann | E. Valeur | F. Narjes
[1] Michele Tinti,et al. ANIA: ANnotation and Integrated Analysis of the 14-3-3 interactome , 2014, Database J. Biol. Databases Curation.
[2] F. Slack,et al. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.
[3] Michal Sharon,et al. Mechanism of auxin perception by the TIR1 ubiquitin ligase , 2007, Nature.
[4] C. Bennett,et al. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.
[5] David M. Wilson,et al. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. , 2018, ACS chemical biology.
[6] Chengqi Yi,et al. Epitranscriptome sequencing technologies: decoding RNA modifications , 2016, Nature Methods.
[7] K. Chien,et al. Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine , 2018, Molecular therapy. Methods & clinical development.
[8] Hiro Furukawa,et al. Subunit Arrangement and Phenylethanolamine Binding in GluN1/GluN2B NMDA Receptors , 2011, Nature.
[9] C. Bieberich,et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. , 2014, Cancer cell.
[10] Martin C Fillmore,et al. Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach. , 2018, ACS chemical biology.
[11] Robert Langer,et al. Delivery technologies for cancer immunotherapy , 2019, Nature Reviews Drug Discovery.
[12] M. Disney,et al. Small Molecule Targeted Recruitment of a Nuclease to RNA. , 2018, Journal of the American Chemical Society.
[13] A. Citri,et al. Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy , 2002, The EMBO journal.
[14] M. Brucale,et al. The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity. , 2014, Human molecular genetics.
[15] T. Natsume,et al. Artificial human Met agonists based on macrocycle scaffolds , 2015, Nature Communications.
[16] Yuzong Chen,et al. Phthalimide conjugations for the degradation of oncogenic PI3K. , 2018, European journal of medicinal chemistry.
[18] Qidong You,et al. Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway. , 2018, European journal of medicinal chemistry.
[19] Stuart L. Schreiber,et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.
[20] U. Rapp,et al. Regulation of RAF Activity by 14-3-3 Proteins , 2009, Journal of Biological Chemistry.
[21] Scott A. Peterson,et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] B. Schwappach,et al. A dual phosphorylation switch controls 14-3-3-dependent cell surface expression of TASK-1 , 2016, Journal of Cell Science.
[23] C. Harmon,et al. Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity , 2018, Nature Communications.
[24] E. Valeur,et al. New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm. , 2018, Journal of medicinal chemistry.
[25] A. Ciulli,et al. SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate , 2019, ACS chemical biology.
[26] A. Dalgleish,et al. Lenalidomide: a novel anticancer drug with multiple modalities , 2009 .
[27] P. Tassone,et al. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches , 2018, Journal of Hematology & Oncology.
[28] H. Lazarus,et al. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development , 2011, Therapeutic advances in hematology.
[29] C. Ottmann,et al. Small‐molecule stabilization of the p53 – 14‐3‐3 protein‐protein interaction , 2017, FEBS letters.
[30] Liu Liu,et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression , 2017, Journal of medicinal chemistry.
[31] J. Kelly,et al. Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.
[32] J. Doudna,et al. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain , 2017, PLoS biology.
[33] S. Carr,et al. Homo-PROTACs for the Chemical Knockdown of Cereblon. , 2018, ACS chemical biology.
[34] Minoru Ishikawa,et al. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. , 2010, Journal of the American Chemical Society.
[35] L. M. Stevers,et al. Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3 and the R domain of CFTR , 2016, Proceedings of the National Academy of Sciences.
[36] Ronald A. Li,et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction , 2013, Nature Biotechnology.
[37] M. Koegl,et al. Chemically Induced Degra dation of the Oncogenic Transcription Factor BCL 6 Graphical Abstract Highlights , 2022 .
[38] L. Jones. Small-Molecule Kinase Downregulators. , 2017, Cell chemical biology.
[39] Yong-Xiang Chen,et al. Hydrophobic tagging-mediated degradation of Alzheimer's disease related Tau , 2017 .
[40] C. Crews,et al. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. , 2008, Bioorganic & medicinal chemistry letters.
[41] Jennifer Doudna,et al. RNA-programmed genome editing in human cells , 2013, eLife.
[42] I. Churcher. Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones? , 2017, Journal of medicinal chemistry.
[43] Michele Tinti,et al. 14-3-3-Pred: improved methods to predict 14-3-3-binding phosphopeptides , 2015, Bioinform..
[44] D. Lamont,et al. Structural basis of PROTAC cooperative recognition for selective protein degradation , 2017, Nature chemical biology.
[45] Sumit Mittal,et al. The Molecular Tweezer CLR01 Stabilizes a Disordered Protein–Protein Interface , 2017, Journal of the American Chemical Society.
[46] C. Dobson,et al. Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.
[47] B. Morgan,et al. Discovery of Small Molecule Ligands for MALAT1 by Tuning an RNA-Binding Scaffold. , 2018, Angewandte Chemie.
[48] Ali Nahvi,et al. Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass Spectrometry. , 2018, ACS chemical biology.
[49] R. Copeland,et al. RNA-modifying proteins as anticancer drug targets , 2018, Nature Reviews Drug Discovery.
[50] J. Acker,et al. Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. , 1999, Molecular cell.
[51] J. Rossi,et al. Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[52] Gary N Parkinson,et al. The application of DNA and RNA G-quadruplexes to therapeutic medicines. , 2011, Chemical Society reviews.
[53] C. Crews,et al. Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy. , 2017, ACS chemical biology.
[54] P. Loria,et al. A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation. , 2016, Cell chemical biology.
[55] C. Crews,et al. Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs) , 2019, ACS central science.
[56] Liu Liu,et al. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. , 2018, Journal of medicinal chemistry.
[57] L. Cantley,et al. Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. , 2013, Molecular cell.
[58] Wei Zhang,et al. Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. , 2018, Journal of medicinal chemistry.
[59] Jeremy L. Jenkins,et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.
[60] A. Fournier,et al. Small-Molecule Stabilization of 14-3-3 Protein-Protein Interactions Stimulates Axon Regeneration , 2017, Neuron.
[61] Michael L Drummond,et al. In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application , 2019, J. Chem. Inf. Model..
[62] M. Mcdougall,et al. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action. , 2018, ACS chemical biology.
[63] A. Fournier,et al. 14‐3‐3 adaptor protein‐protein interactions as therapeutic targets for CNS diseases , 2017, Pharmacological research.
[64] James E. Bradner,et al. Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.
[65] Herbert Waldmann,et al. New Modalities for Challenging Targets in Drug Discovery. , 2017, Angewandte Chemie.
[66] Jian Min,et al. New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. , 2018, ACS medicinal chemistry letters.
[67] R. M. Sharrard,et al. Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex. , 2000, Journal of molecular endocrinology.
[68] Craig M. Crews,et al. Induced protein degradation: an emerging drug discovery paradigm , 2016, Nature Reviews Drug Discovery.
[69] M. Gütschow,et al. PROTAC-mediated crosstalk between E3 ligases. , 2019, Chemical communications.
[70] D. Curtis,et al. Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). , 2018, Journal of medicinal chemistry.
[71] C. Crews,et al. Inducing Protein Degradation as a Therapeutic Strategy. , 2016, Journal of medicinal chemistry.
[72] A. D. Boer,et al. Fusicoccanes: diterpenes with surprising biological functions , 2012 .
[73] Matthew D Disney,et al. Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit. , 2017, Journal of the American Chemical Society.
[74] M. Koegl,et al. Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions. , 2019, Journal of medicinal chemistry.
[75] C. Ottmann,et al. Stabilization of Protein-Protein Interactions in chemical biology and drug discovery. , 2015, Progress in biophysics and molecular biology.
[76] R. Place,et al. Small dsRNAs induce transcriptional activation in human cells , 2006, Proceedings of the National Academy of Sciences.
[77] James E. Bradner,et al. Plasticity in binding confers selectivity in ligand induced protein degradation , 2018, Nature Chemical Biology.
[78] Emilio Alba,et al. The Functional Interaction of 14-3-3 Proteins with the ERK1/2 Scaffold KSR1 Occurs in an Isoform-specific Manner* , 2008, Journal of Biological Chemistry.
[79] C. Ottmann,et al. A semisynthetic fusicoccane stabilizes a protein-protein interaction and enhances the expression of K+ channels at the cell surface. , 2013, Chemistry & biology.
[80] Christopher J. Ott,et al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands , 2018, Nature Chemical Biology.
[81] Luke A. Gilbert,et al. CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.
[82] C. Ottmann,et al. Molecular tweezers modulate 14-3-3 protein-protein interactions. , 2013, Nature chemistry.
[83] M. Disney,et al. Recent advances in developing small molecules targeting RNA. , 2012, ACS chemical biology.
[84] C. Dominguez,et al. Identification of G-quadruplexes in long functional RNAs using 7-deaza-Guanine RNA , 2016, Nature chemical biology.
[85] Eric T. Wang,et al. Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model , 2019, Proceedings of the National Academy of Sciences.
[86] W. Zwart,et al. Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface , 2013, Proceedings of the National Academy of Sciences.
[87] Jing Wang,et al. The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. , 2017, Cell chemical biology.
[88] S. Solomon,et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.
[89] C. Ottmann,et al. Rationally Designed Semisynthetic Natural Product Analogues for Stabilization of 14-3-3 Protein-Protein Interactions. , 2018, Angewandte Chemie.
[90] J. Ovádi,et al. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). , 2017, Journal of medicinal chemistry.
[91] I. E. Smith,et al. PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding. , 2019, ACS chemical biology.
[92] T. Corson,et al. Small-Molecule Hydrophobic Tagging Induced Degradation of HaloTag Fusion Proteins , 2011, Nature Chemical Biology.
[93] L. M. Stevers,et al. Modulators of 14-3-3 Protein–Protein Interactions , 2017, Journal of medicinal chemistry.
[94] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[95] J. Rizo,et al. Jasmonate perception by inositol phosphate-potentiated COI1-JAZ co-receptor , 2010, Nature.
[96] Robert Langer,et al. Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium , 2019, Advanced materials.
[97] M. Ueffing,et al. Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3 , 2013, Proceedings of the National Academy of Sciences.
[98] James E. DiCarlo,et al. RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.
[99] N. Gray,et al. Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML. , 2019, Cell chemical biology.
[100] A. Ciulli,et al. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 , 2015, ACS chemical biology.
[101] P. Workman,et al. Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766) , 2017, Journal of medicinal chemistry.
[102] Shaomeng Wang,et al. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). , 2019, Journal of medicinal chemistry.
[103] K. Chien,et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes , 2019, Nature Communications.
[104] A. Prasad,et al. Nucleic acid therapeutics: basic concepts and recent developments , 2014 .
[105] D. Alessi,et al. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation , 2017, Nature Communications.
[106] L. Hedstrom,et al. Boc3Arg-Linked Ligands Induce Degradation by Localizing Target Proteins to the 20S Proteasome. , 2016, ACS chemical biology.
[107] R. Young,et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. , 2017, Nature chemical biology.
[108] Yanchang Wang,et al. 14-3-3 protein targets misfolded chaperone-associated proteins to aggresomes , 2013, Journal of Cell Science.
[109] James C Sacchettini,et al. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. , 2004, Journal of medicinal chemistry.
[110] Vincent L. Butty,et al. Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription. , 2019, Cell chemical biology.
[111] Michael Reutlinger,et al. Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA). , 2018, Journal of medicinal chemistry.
[112] T. Tsuruo,et al. Small Molecules Destabilize cIAP1 by Activating Auto-ubiquitylation* , 2008, Journal of Biological Chemistry.
[113] S. Carr,et al. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.
[114] Y. T. Wang,et al. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation , 2014, Nature Neuroscience.
[115] G. Petzold,et al. Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase , 2016, Nature.
[116] Yong-Xiang Chen,et al. TDP-43 specific reduction induced by Di-hydrophobic tags conjugated peptides. , 2019, Bioorganic chemistry.
[117] Charles H Jones,et al. Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors. , 2016, Trends in biotechnology.
[118] S. Fisher,et al. Targeted protein degradation and the enzymology of degraders. , 2018, Current opinion in chemical biology.
[119] M. Skwarczynska,et al. Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers. , 2013, ACS chemical biology.
[120] Y. Xiong,et al. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). , 2018, European journal of medicinal chemistry.
[121] Jeffrey Skolnick,et al. The distribution of ligand-binding pockets around protein-protein interfaces suggests a general mechanism for pocket formation , 2012, Proceedings of the National Academy of Sciences.
[122] Alexander Meissner,et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.
[123] Stuart L. Schreiber,et al. A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.
[124] L. Pusztai,et al. The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming , 2015, Nature Communications.
[125] W. Gilbert,et al. Messenger RNA modifications: Form, distribution, and function , 2016, Science.
[126] Kathleen A. Boyle,et al. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction , 2019, Nature Communications.
[127] Gaurav Sahay,et al. Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[128] Jonas Korlach,et al. The birth of the Epitranscriptome: deciphering the function of RNA modifications , 2012, Genome Biology.
[129] N. Rizvi,et al. RNA as a small molecule druggable target. , 2017, Bioorganic & medicinal chemistry letters.
[130] Anirvan Ghosh,et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy , 2014, Science.
[131] Michael Hann,et al. Stabilization of protein-protein interactions in drug discovery , 2017, Expert opinion on drug discovery.
[132] Lukasz Skóra,et al. Site-Directed Fragment-Based Screening for the Discovery of Protein-Protein Interaction Stabilizers. , 2019, Journal of the American Chemical Society.
[133] M. Disney,et al. Precise Small Molecule Degradation of a Noncoding RNA Identifies Cellular Binding Sites and Modulates an Oncogenic Phenotype. , 2018, ACS chemical biology.
[134] Shaomeng Wang,et al. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. , 2019, Journal of medicinal chemistry.
[135] M. Schapira. Structural Chemistry of Human RNA Methyltransferases. , 2016, ACS chemical biology.
[136] Salvador Ventura,et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity , 2016, Nature Communications.
[137] D. Spector,et al. Selective Small-Molecule Targeting of a Triple Helix Encoded by the Long Noncoding RNA, MALAT1. , 2019, ACS chemical biology.
[138] K. Weeks,et al. Principles for targeting RNA with drug-like small molecules , 2018, Nature Reviews Drug Discovery.
[139] Lukasz Skóra,et al. Identification of Two Secondary Ligand Binding Sites in 14-3-3 Proteins Using Fragment Screening , 2017, Biochemistry.
[140] A. Ciulli,et al. 3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation , 2018, Journal of the American Chemical Society.
[141] A. Gregory Matera,et al. A day in the life of the spliceosome , 2014, Nature Reviews Molecular Cell Biology.
[142] H. Zoghbi,et al. Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3ε haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration , 2011, Proceedings of the National Academy of Sciences.
[143] Özlem Türeci,et al. mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.
[144] T. Veenstra,et al. Protein Phosphatase 2A Positively Regulates Ras Signaling by Dephosphorylating KSR1 and Raf-1 on Critical 14-3-3 Binding Sites , 2003, Current Biology.
[145] Thomas M. Smith,et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. , 2015, Nature chemical biology.
[146] Covalent small-molecule-RNA complex formation enables cellular profiling of small-molecule-RNA interactions. , 2013, Angewandte Chemie.
[147] C. Crews,et al. Chemical biology: Greasy tags for protein removal , 2012, Nature.
[148] J. Doudna,et al. The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.
[149] Chad J. Miller,et al. A comprehensive mathematical model for three-body binding equilibria. , 2013, Journal of the American Chemical Society.
[150] C. Ottmann,et al. Structural characterization of 14-3-3ζ in complex with the human Son of sevenless homolog 1 (SOS1). , 2018, Journal of structural biology.
[151] R. Labaudinière,et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.
[152] J. Doudna,et al. Cornerstones of CRISPR–Cas in drug discovery and therapy , 2016, Nature Reviews Drug Discovery.
[153] N. Leclerc,et al. Interaction of 14-3-3ζ with microtubule-associated protein tau within Alzheimer's disease neurofibrillary tangles. , 2013, Biochemistry.
[154] N. Dumaz,et al. Protein Kinase A Blocks Raf-1 Activity by Stimulating 14-3-3 Binding and Blocking Raf-1 Interaction with Ras* , 2003, Journal of Biological Chemistry.
[155] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[156] C. Loh,et al. Targeted protein degradation mechanisms. , 2019, Drug discovery today. Technologies.
[157] L. Camoni,et al. The phytotoxin fusicoccin, a selective stabilizer of 14‐3‐3 interactions? , 2013, IUBMB life.
[158] Irene Lostalé‐Seijo,et al. Synthetic materials at the forefront of gene delivery , 2018, Nature Reviews Chemistry.
[159] Hiroki Kato,et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[160] Kenneth P Nephew,et al. Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate Immobilization and Degradation of Estrogen Receptor-α* , 2006, Journal of Biological Chemistry.
[161] P. Jänne,et al. Pharmacological Targeting of the Pseudokinase Her3 , 2014, Nature chemical biology.
[162] C. Crews,et al. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase , 2019, Nature Communications.
[163] Liu Liu,et al. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. , 2018, Journal of Medicinal Chemistry.
[164] Weiping Tang,et al. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. , 2018, Bioorganic & medicinal chemistry letters.
[165] A. Rabow,et al. Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist. , 2015, Journal of medicinal chemistry.
[166] C. Crews,et al. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. , 2017, Cell chemical biology.
[167] W. L. Jorgensen,et al. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. , 2012, Angewandte Chemie.
[168] R. J. Ramamurthi,et al. Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.
[169] Philippe P Roux,et al. RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation. , 2012, The Biochemical journal.
[170] K. Read,et al. Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrroli , 2017, Journal of medicinal chemistry.
[171] Dennis L. Buckley,et al. Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. , 2015, Angewandte Chemie.
[172] Markus Kaiser,et al. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? , 2012, Angewandte Chemie.
[173] Francine E. Garrett-Bakelman,et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal and leukemia cells , 2017, Nature Medicine.
[174] S R Sprang,et al. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. , 1997 .
[175] C. Ottmann,et al. Small‐Molecule Stabilization of the 14‐3‐3/Gab2 Protein–Protein Interaction (PPI) Interface , 2016, ChemMedChem.
[176] A. Ciulli,et al. Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders , 2017, Essays in biochemistry.
[177] R. Falk,et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. , 2005, Archives of internal medicine.
[178] J. Berger,et al. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[179] A. Plowright,et al. Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum. , 2017, Cell chemical biology.
[180] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.